Coeptis Therapeutics Holdings Becomes COEPTIS: Embracing a Future of Technology and Innovation
Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced its rebranding to COEPTIS, signaling a strategic expansion beyond biopharmaceuticals into technology-driven sectors. The company has established a new Technology Division, marked by the acquisition of the NexGenAI Affiliates Network platform, an AI-powered marketing solution.
The transformation aims to enhance operational capabilities and maximize shareholder value through technology integration. The NexGenAI platform will provide AI-driven marketing solutions for highly regulated industries, while the Technology Division focuses on developing automation capabilities and AI agents to optimize workflows.
According to CEO Dave Mehalick, this strategic shift aims to create revenue-generating, cash flow-positive business units, positioning COEPTIS as a self-sustaining entity. The company's technology suite includes AI-driven marketing software, robotic process automation (RPA), and data analytics tools designed to enhance communication strategies and drive sustainable growth.
Coeptis Therapeutics Holdings (NASDAQ: COEP) ha annunciato il suo rebranding in COEPTIS, segnando un'espansione strategica oltre il settore dei farmaci biopharmaceuticals verso settori guidati dalla tecnologia. L'azienda ha istituito una nuova Divisione Tecnologica, caratterizzata dall'acquisizione della piattaforma NexGenAI Affiliates Network, una soluzione di marketing potenziata dall'IA.
Questa trasformazione mira a migliorare le capacità operative e massimizzare il valore per gli azionisti attraverso l'integrazione della tecnologia. La piattaforma NexGenAI fornirà soluzioni di marketing guidate dall'IA per settori altamente regolamentati, mentre la Divisione Tecnologica si concentra sullo sviluppo di capacità di automazione e agenti IA per ottimizzare i flussi di lavoro.
Secondo il CEO Dave Mehalick, questo cambiamento strategico mira a creare unità aziendali generatrici di entrate e positive per il flusso di cassa, posizionando COEPTIS come un'entità autosufficiente. Il pacchetto tecnologico dell'azienda include software di marketing guidato dall'IA, automazione dei processi robotici (RPA) e strumenti di analisi dei dati progettati per migliorare le strategie di comunicazione e guidare una crescita sostenibile.
Coeptis Therapeutics Holdings (NASDAQ: COEP) ha anunciado su cambio de marca a COEPTIS, señalando una expansión estratégica más allá de los productos biofarmacéuticos hacia sectores impulsados por la tecnología. La empresa ha establecido una nueva División de Tecnología, marcada por la adquisición de la plataforma NexGenAI Affiliates Network, una solución de marketing impulsada por IA.
La transformación tiene como objetivo mejorar las capacidades operativas y maximizar el valor para los accionistas a través de la integración tecnológica. La plataforma NexGenAI proporcionará soluciones de marketing impulsadas por IA para industrias altamente reguladas, mientras que la División de Tecnología se centra en desarrollar capacidades de automatización y agentes IA para optimizar los flujos de trabajo.
Según el CEO Dave Mehalick, este cambio estratégico busca crear unidades de negocio generadoras de ingresos y positivas en flujo de caja, posicionando a COEPTIS como una entidad autosuficiente. El conjunto tecnológico de la empresa incluye software de marketing impulsado por IA, automatización de procesos robotizados (RPA) y herramientas de análisis de datos diseñadas para mejorar las estrategias de comunicación y fomentar un crecimiento sostenible.
Coeptis Therapeutics Holdings (NASDAQ: COEP)는 COEPTIS로 브랜드를 전환한다고 발표하며, 생물의약품을 넘어 기술 기반 분야로의 전략적 확장을 나타냈습니다. 이 회사는 NexGenAI Affiliates Network 플랫폼을 인수하여 새로운 기술 부서를 설립했습니다. 이는 AI 기반의 마케팅 솔루션입니다.
이 변화는 운영 능력을 향상시키고 기술 통합을 통해 주주 가치를 극대화하는 것을 목표로 하고 있습니다. NexGenAI 플랫폼은 규제가 엄격한 산업을 위한 AI 기반의 마케팅 솔루션을 제공하며, 기술 부서는 워크플로우 최적화를 위해 자동화 기능과 AI 에이전트를 개발하는 데 중점을 둡니다.
CEO 데이브 메할릭(Dave Mehalick)에 따르면, 이 전략적 전환은 수익 창출과 긍정적인 현금을 생성하는 비즈니스 유닛을 만드는 것을 목표로 하며, COEPTIS를 자립적인 조직으로서 자리매김하게 합니다. 회사의 기술 스위트에는 AI 기반의 마케팅 소프트웨어, 로보틱 프로세스 자동화(RPA) 및 전략적 커뮤니케이션을 개선하고 지속 가능한 성장을 촉진하기 위한 데이터 분석 도구가 포함됩니다.
Coeptis Therapeutics Holdings (NASDAQ: COEP) a annoncé son changement de marque en COEPTIS, signalant une expansion stratégique au-delà des bio-pharmaceutiques vers des secteurs axés sur la technologie. L'entreprise a établi une nouvelle division technologique, marquée par l'acquisition de la plateforme NexGenAI Affiliates Network, une solution de marketing propulsée par l'IA.
Cette transformation vise à améliorer les capacités opérationnelles et à maximiser la valeur pour les actionnaires grâce à l'intégration technologique. La plateforme NexGenAI fournira des solutions de marketing basées sur l'IA pour des industries hautement régulées, tandis que la division technologique se concentre sur le développement de capacités d'automatisation et d'agents IA pour optimiser les flux de travail.
Selon le PDG Dave Mehalick, ce changement stratégique vise à créer des unités commerciales génératrices de revenus et positives en termes de cash flow, positionnant COEPTIS comme une entité autosuffisante. La suite technologique de l'entreprise comprend un logiciel de marketing propulsé par l'IA, une automatisation des processus robotiques (RPA) et des outils d'analyse de données conçus pour améliorer les stratégies de communication et favoriser une croissance durable.
Coeptis Therapeutics Holdings (NASDAQ: COEP) hat die Umbenennung in COEPTIS angekündigt, was eine strategische Expansion über biopharmazeutische Produkte hinaus in technologiegetriebene Sektoren signalisiert. Das Unternehmen hat eine neue Technologiedivision gegründet, die durch die Übernahme der NexGenAI Affiliates Network Plattform, einer KI-gestützten Marketinglösung, gekennzeichnet ist.
Die Transformation zielt darauf ab, die operativen Fähigkeiten zu verbessern und den Aktionärswert durch Technologieintegration zu maximieren. Die NexGenAI-Plattform wird KI-gestützte Marketinglösungen für stark regulierte Branchen bereitstellen, während die Technologiedivision sich auf die Entwicklung von Automatisierungsfähigkeiten und KI-Agenten konzentriert, um Arbeitsabläufe zu optimieren.
Laut CEO Dave Mehalick zielt dieser strategische Wandel darauf ab, ertragsgenerierende, cashflow-positive Geschäftseinheiten zu schaffen und COEPTIS als selbsttragende Einheit zu positionieren. Der technische Bereich des Unternehmens umfasst KI-gestützte Marketingsoftware, robotergestützte Prozessautomatisierung (RPA) und Datenanalyse-Tools, die entwickelt wurden, um Kommunikationsstrategien zu verbessern und nachhaltiges Wachstum zu fördern.
- Strategic expansion into technology sector through new Technology Division
- Acquisition of NexGenAI Affiliates Network platform for revenue generation
- Development of AI and automation capabilities for operational efficiency
- Focus on creating cash flow-positive business units
- Significant shift from core biopharmaceutical business model introduces execution risks
- Potential dilution of focus from original pharmaceutical development mission
Rebranding Signals Strategic Shift Beyond Biopharmaceuticals, Highlights Commitment to Technology, Artificial Intelligence and Shareholder Value
With the establishment of our new Technology Division, COEPTIS aims to enhance operational capabilities and maximize shareholder value. Central to this initiative was the recent acquisition of the NexGenAI Affiliates Network platform, a groundbreaking AI-powered marketing solution. This acquisition aligns seamlessly with COEPTIS's mission to innovate in highly regulated industries, revolutionizing marketing strategies and operational efficiencies.
By integrating NexGenAI's advanced tools, COEPTIS empowers companies to tackle marketing challenges in competitive landscapes with AI-driven precision and efficiency. Building on this foundation, our Technology Division is expanding its automation capabilities and developing AI agents to optimize workflows and drive operational efficiency through intelligent automation.
Dave Mehalick, President and CEO of Coeptis, stated, "This strategic move not only reinforces our commitment to innovation but also strengthens our efforts to expand into revenue-generating, cash flow-positive business units. By leveraging cutting-edge technologies, we are positioning COEPTIS as a self-sustaining entity, creating a robust foundation for long-term growth and profitability."
"NexGenAI Affiliates Network stands apart as a trailblazer in delivering practical, transformative AI solutions tailored for real-world business needs. Unlike traditional AI firms focused on narrow applications or theoretical advancements, Coeptis Technologies leverages a proprietary suite of advanced technologies; including AI-driven marketing software, robotic process automation (RPA), and actionable data analytics—to empower businesses across diverse sectors. Our platform is designed not just to automate processes, but to enhance communication strategies, optimize campaigns, and drive sustainable growth and we remain committed to responsible innovation harnessing the power of technology to create meaningful impact and deliver tangible value." added Mr. Mehalick.
About Coeptis Therapeutics Holdings, Inc.
Coeptis Therapeutics Holdings, Inc., together with its subsidiaries including Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc., and SNAP Biosciences, Inc. (collectively "Coeptis"), is a biopharmaceutical and technology company focused on developing innovative cell therapy platforms for cancer, autoimmune, and infectious diseases. Coeptis aims to advance treatment paradigms and improve patient outcomes through its cutting-edge research and development efforts.
The Company's therapeutic portfolio is underscored by assets licensed from Deverra Therapeutics, which include an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. Coeptis is also developing a universal, multi-antigen CAR technology licensed from the University of
Building on its core competencies, Coeptis has recently established a Technology Division, which focuses on enhancing operational capabilities through advanced technologies. This division features AI-powered marketing software and robotic process automation tools acquired from NexGenAI Solutions Group, designed to optimize business processes and improve overall efficiency.
Headquartered in
Cautionary Note Regarding Forward-Looking Statements
This press release and statements of our management made in connection therewith contain or may contain "forward-looking statements" (as defined in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended). Forward-looking statements include statements concerning our plans, objectives, goals, strategies, future events or performance, and underlying assumptions, and other statements that are other than statements of historical facts. When we use words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, we are making forward-looking statements. Forward-looking statements are not a guarantee of future performance and involve significant risks and uncertainties that may cause the actual results to differ materially and perhaps substantially from our expectations discussed in the forward-looking statements. Factors that may cause such differences include but are not limited to: (1) the inability to maintain the listing of the Company's securities on the Nasdaq Capital Market; (2) the inability to recognize the anticipated benefits of the Deverra licensed assets, which may be affected by, among other things, competition, the ability of the Company to grow and manage growth economically and hire and retain key employees; (3) the risks that the Company's products in development or the newly-licensed assets fail clinical trials or are not approved by the
Contacts
IR@coeptistx.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/coeptis-therapeutics-holdings-becomes-coeptis-embracing-a-future-of-technology-and-innovation-302364358.html
SOURCE Coeptis Therapeutics, Inc.
FAQ
What is the significance of Coeptis Therapeutics (COEP) rebranding to COEPTIS?
How will the NexGenAI acquisition impact COEP's business model?
What new technologies is COEP implementing in its Technology Division?
How does COEP's strategic shift affect its revenue potential?
